Helicobacter pylori: past, current and future treatment strategies with gastroretentive drug delivery systems

Helicobacter pylori have been subject to intense investigation since its discovery from gastric biopsy in 1982. This gastropathogen has been regarded as serious public health problem due to its association with dyspepsia, gastritis, gastroduodenal ulcers, mucus-associated lymphoid tissue lymphoma an...

Full description

Saved in:
Bibliographic Details
Published inJournal of drug targeting Vol. 24; no. 10; pp. 897 - 915
Main Authors Verma, Anurag, Dubey, Juhi, Hegde, Rahul Rama, Rastogi, Vaibhav, Pandit, J. K.
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 25.11.2016
Subjects
Adhesive systems
Antacids - administration & dosage
Antacids - pharmacokinetics
Antacids - therapeutic use
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - therapeutic use
Drug Delivery Systems - methods
Drug Resistance, Multiple, Bacterial
Drug Therapy, Combination
Gastric Mucosa - drug effects
Gastric Mucosa - metabolism
Gastric Mucosa - microbiology
GRDDS
H. pylori
Helicobacter Infections - drug therapy
Helicobacter Infections - microbiology
Helicobacter pylori - drug effects
Humans
in situ gelling systems
polymeric rafts
Proton Pump Inhibitors - administration & dosage
Proton Pump Inhibitors - pharmacokinetics
Proton Pump Inhibitors - therapeutic use
H. pylori
polymeric rafts
in situ gelling systems
GRDDS
Adhesive systems
Online AccessGet full text

Cover

Abstract Helicobacter pylori have been subject to intense investigation since its discovery from gastric biopsy in 1982. This gastropathogen has been regarded as serious public health problem due to its association with dyspepsia, gastritis, gastroduodenal ulcers, mucus-associated lymphoid tissue lymphoma and gastric carcinoma. In vivo eradication of established H. pylori infections is difficult due to several factors such as gastric niche, coccoid form due to sub-minimum inhibitory concentration of antimicrobials, bacterial load, primary antibiotic resistance, patient compliance and stability of therapeutics in gastric acid secretion. Considering these factors, a logical way to improve the outcome of the treatment is to develop dosage forms which are able to deliver the anti-helicobacter agents in the gastric niche for both local and systemic actions, simultaneously taking care of stability of therapeutics in acidic environment. Such dosage forms, which are popularly known as gastro retentive drug delivery systems (GRDDS), have the immense potential to effectively counter the problem of high bacterial load; prevent induction of coccoid bacteria thereby improving treatment outcome and compliance. This review describes efficacy of various therapeutic agents, treatment strategies and status of different GRDDS until now.
AbstractList Helicobacter pylori have been subject to intense investigation since its discovery from gastric biopsy in 1982. This gastropathogen has been regarded as serious public health problem due to its association with dyspepsia, gastritis, gastroduodenal ulcers, mucus-associated lymphoid tissue lymphoma and gastric carcinoma. In vivo eradication of established H. pylori infections is difficult due to several factors such as gastric niche, coccoid form due to sub-minimum inhibitory concentration of antimicrobials, bacterial load, primary antibiotic resistance, patient compliance and stability of therapeutics in gastric acid secretion. Considering these factors, a logical way to improve the outcome of the treatment is to develop dosage forms which are able to deliver the anti-helicobacter agents in the gastric niche for both local and systemic actions, simultaneously taking care of stability of therapeutics in acidic environment. Such dosage forms, which are popularly known as gastro retentive drug delivery systems (GRDDS), have the immense potential to effectively counter the problem of high bacterial load; prevent induction of coccoid bacteria thereby improving treatment outcome and compliance. This review describes efficacy of various therapeutic agents, treatment strategies and status of different GRDDS until now.
Author Hegde, Rahul Rama
Dubey, Juhi
Verma, Anurag
Rastogi, Vaibhav
Pandit, J. K.
Author_xml – sequence: 1
  givenname: Anurag
  surname: Verma
  fullname: Verma, Anurag
  email: anuragverma_iftm@yahoo.co.in, rahulhpharma@gmail.com
  organization: Department of Pharmaceutics, College of Pharmacy, IFTM
– sequence: 2
  givenname: Juhi
  surname: Dubey
  fullname: Dubey, Juhi
  organization: Department of Pharmaceutics, College of Pharmacy, IFTM
– sequence: 3
  givenname: Rahul Rama
  surname: Hegde
  fullname: Hegde, Rahul Rama
  email: anuragverma_iftm@yahoo.co.in, rahulhpharma@gmail.com
  organization: Department of Quality Assurance, Lupin Ltd, Verna
– sequence: 4
  givenname: Vaibhav
  surname: Rastogi
  fullname: Rastogi, Vaibhav
  organization: Department of Pharmaceutics, College of Pharmacy, IFTM
– sequence: 5
  givenname: J. K.
  surname: Pandit
  fullname: Pandit, J. K.
  organization: Department of Pharmaceutics, Institute of Technology, Banaras Hindu University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27027827$$D View this record in MEDLINE/PubMed
BookMark eNqFkMtqHDEQRUWwiR_JJyToA9JjldSj7kk2McaJDYZsEshO6FGaKPRjKKlt5u_dzXg2WcTUogrpnlvUvWAnwzggYx9ArBSIzRUIDdDq3yspQK8AGlBSv2HnIOSmkkqJk2XWUC2iM3aR818hQGkQb9mZbIRsWtmcs_4Ou-RHZ31B4rt9N1L6zHc2l0_cT0Q4FG6HwONUJkJeCG3pl8dcyBbcJsz8KZU_fDsjNBKW-TM9Ig80bXmYzR-R9jzvc8E-v2On0XYZ37_0S_br2-3Pm7vq4cf3-5vrh8orrUulXaOUb6RDh8oFWTuxmQutA9SuDc5hHea-hnqz1kE0tW_rKGKU2usWorpkHw--u8n1GMyOUm9pb453z4IvB4GnMWfCaHwqtqRxmM9KnQFhlpTNMWWzpGxeUp7p9T_0ccFr3NcDl4Y4Um-fRuqCKXZJPZIdfMoL_j-LZ0Nhlw8
CitedBy_id crossref_primary_10_1016_j_ijbiomac_2022_02_039
crossref_primary_10_1016_j_heliyon_2023_e20406
crossref_primary_10_1007_s12247_024_09820_2
crossref_primary_10_1007_s00253_020_10945_w
crossref_primary_10_1097_QCO_0000000000000396
crossref_primary_10_1016_j_jconrel_2022_06_005
crossref_primary_10_1007_s10337_024_04346_8
crossref_primary_10_1590_s2175_97902022e18630
crossref_primary_10_1016_j_ejpb_2024_114313
crossref_primary_10_1080_1061186X_2024_2347366
crossref_primary_10_1007_s12247_023_09776_9
crossref_primary_10_1039_D1TB02038B
crossref_primary_10_1016_j_arabjc_2022_103685
crossref_primary_10_3390_ma15196521
crossref_primary_10_1016_j_jddst_2020_102219
crossref_primary_10_3390_pathogens9090747
crossref_primary_10_1016_j_ijbiomac_2025_142197
crossref_primary_10_3390_pharmaceutics16060790
crossref_primary_10_1039_D3CC00933E
crossref_primary_10_1208_s12249_019_1607_5
Cites_doi 10.2460/ajvr.1982.43.11.2028
10.1016/S0939-6411(01)00124-2
10.1136/gut.2003.022111
10.1016/j.jsps.2011.01.004
10.1016/j.dld.2005.03.007
10.3109/10717544.2014.916766
10.1208/s12249-008-9038-8
10.1248/cpb.57.1068
10.1016/j.biomaterials.2016.01.045
10.3109/03639045.2015.1054397
10.2217/fmb.10.25
10.1007/BF02300360
10.3109/02652048.2013.805840
10.1016/S0168-1605(99)00160-9
10.1046/j.1365-2036.2002.01165.x
10.1016/j.ijpharm.2013.11.053
10.1016/S1590-8658(01)80139-0
10.1016/j.biomaterials.2013.02.028
10.3109/00365529609094541
10.1081/DMR-100104401
10.1002/jbm.b.30134
10.1208/pt060347
10.1016/0168-3659(85)90061-6
10.1080/107175400455173
10.1016/j.colsurfb.2016.01.048
10.1016/S0140-6736(84)91816-6
10.1111/j.1083-4389.2004.00251.x
10.1136/gutjnl-2012-302254
10.1016/j.jconrel.2004.06.022
10.1080/10717540260397837
10.1097/00004836-200304000-00009
10.1016/j.ijpharm.2015.04.004
10.1016/j.jsps.2014.02.009
10.1053/jinf.2002.1047
10.3109/03639049409038361
10.1016/j.ijpharm.2014.01.024
10.1016/S0378-5173(98)00400-1
10.1016/j.jconrel.2005.10.031
10.1053/gast.1996.v111.agast961110521
10.1016/j.actbio.2013.07.034
10.1136/gut.2006.101634
10.1081/PDT-120022154
10.1023/A:1018939512213
10.1007/s10620-014-3063-0
10.1111/jphp.12345
10.3109/10837450903196843
10.1128/IAI.65.9.3672-3679.1997
10.1016/j.ijpharm.2013.12.052
10.1016/j.ijpharm.2006.11.008
10.1093/jac/34.6.1025
10.1007/BF01964416
10.1046/j.1365-2036.2003.01655.x
10.1080/713840399
10.1016/j.ijpharm.2014.04.070
10.1046/j.1365-2036.2000.00846.x
10.1248/cpb.56.1412
10.1163/156856209X415855
10.1146/annurev.micro.54.1.615
10.1021/mp5000339
10.1093/oxfordjournals.epirev.a018040
10.1016/j.actbio.2010.08.028
10.1016/S1590-8658(03)00432-8
10.4292/wjgpt.v3.i4.68
10.1016/j.ejpb.2015.07.020
10.1211/0022357011775163
10.1046/j.1365-2036.2000.00719.x
10.1023/A:1015981627525
10.7326/0003-4819-148-12-200806170-00226
10.1002/jps.2600770802
10.1016/S0168-3659(99)00139-X
10.1007/BF03259398
10.1208/s12249-012-9882-4
10.1016/S0168-3659(97)00266-6
10.1358/mf.2006.28.7.1003574
10.1159/000236024
10.1016/j.procbio.2012.05.019
10.1046/j.1365-2036.2002.01169.x
10.1111/j.1365-2036.2005.02522.x
10.1111/j.1365-2036.2004.02077.x
10.4166/kjg.2014.63.2.82
10.2478/v10007-007-0033-5
10.1016/j.dld.2004.09.008
10.1016/S0939-6411(03)00097-3
10.1016/0168-3659(96)01344-2
10.1111/j.1365-2036.2005.02656.x
10.1016/S0378-5173(01)00985-1
10.1002/app.24319
10.1016/0016-5085(85)90342-7
10.1016/S0168-3659(99)00204-7
10.1002/mabi.200600164
10.1016/j.jconrel.2007.07.011
10.1517/17425247.3.2.217
10.1016/0168-3659(96)01343-0
10.1111/j.1523-5378.2006.00407.x
10.1208/s12249-009-9231-4
10.1111/j.1365-2036.2005.02412.x
10.1128/AAC.42.10.2492
10.1046/j.1365-2036.2000.00791.x
10.1016/j.ijpharm.2003.12.026
10.1021/bm5012618
10.1016/j.ijpharm.2003.12.001
10.1021/mp500242q
10.1021/mp800193n
10.1208/s12249-011-9730-y
ContentType Journal Article
Copyright 2016 Informa UK Limited, trading as Taylor & Francis Group 2016
Copyright_xml – notice: 2016 Informa UK Limited, trading as Taylor & Francis Group 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.3109/1061186X.2016.1171326
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1029-2330
EndPage 915
ExternalDocumentID 27027827
10_3109_1061186X_2016_1171326
1171326
Genre Review
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
29K
36B
4.4
53G
5GY
AALUX
AAMIU
AAPUL
AAPXX
AAQRR
ABBKH
ABDBF
ABEIZ
ABJNI
ABLIJ
ABLKL
ABUPF
ABXYU
ACENM
ACGEJ
ACGFS
ACIEZ
ACUHS
ADCVX
ADRBQ
ADXPE
AECIN
AENEX
AEOZL
AFKVX
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJWEG
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
ALYBC
BABNJ
BLEHA
BOHLJ
CCCUG
CS3
D-I
DKSSO
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
M4Z
O9-
RNANH
RVRKI
SV3
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUROJ
TUS
UHWXJ
V1S
~1N
AAGDL
AAYXX
ABWVI
AFRVT
CITATION
TASJS
0VX
5VS
AACCU
AALIY
ABCRQ
ACKYO
ADYSH
AFAUU
AFQCT
AGAFX
AJEBJ
AJXHO
AWYRJ
BVLLS
CAG
CGR
COF
CUY
CVF
DEIEU
DLVIE
DTRLO
DZHFC
ECM
EIF
JFOCU
LJTGL
M44
NPM
NUSFT
QRXOQ
ID FETCH-LOGICAL-c366t-6b733c72bebe3bd24b09090eab1e6b8dbbe4db8d514956d074c84f0ff26c681f3
ISSN 1061-186X
IngestDate Wed Feb 19 02:44:18 EST 2025
Sun Aug 03 02:36:44 EDT 2025
Thu Apr 24 23:07:42 EDT 2025
Wed Dec 25 09:02:58 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords H. pylori
polymeric rafts
in situ gelling systems
GRDDS
Adhesive systems
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c366t-6b733c72bebe3bd24b09090eab1e6b8dbbe4db8d514956d074c84f0ff26c681f3
PMID 27027827
PageCount 19
ParticipantIDs crossref_citationtrail_10_3109_1061186X_2016_1171326
informaworld_taylorfrancis_310_3109_1061186X_2016_1171326
crossref_primary_10_3109_1061186X_2016_1171326
pubmed_primary_27027827
PublicationCentury 2000
PublicationDate 2016-11-25
PublicationDateYYYYMMDD 2016-11-25
PublicationDate_xml – month: 11
  year: 2016
  text: 2016-11-25
  day: 25
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of drug targeting
PublicationTitleAlternate J Drug Target
PublicationYear 2016
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References CIT0072
CIT0071
CIT0074
CIT0073
CIT0076
CIT0075
CIT0078
CIT0111
CIT0077
CIT0110
CIT0070
Bhaskar KR (CIT0030) 1991; 261
Hwang SJ (CIT0107) 1998; 15
CIT0113
CIT0079
CIT0112
CIT0115
CIT0114
CIT0117
CIT0116
Xu WL (CIT0060) 1991; 26
CIT0118
CIT0083
CIT0082
CIT0085
CIT0084
CIT0087
CIT0120
CIT0086
CIT0001
CIT0089
CIT0122
CIT0088
CIT0121
CIT0081
CIT0080
CIT0003
CIT0124
CIT0123
CIT0005
CIT0126
CIT0004
CIT0125
CIT0007
CIT0128
CIT0006
Riner JL (CIT0045) 1982; 43
CIT0127
CIT0009
CIT0008
CIT0129
Mardigan MT (CIT0002) 2000
CIT0094
CIT0093
CIT0096
CIT0095
CIT0098
CIT0131
CIT0097
CIT0130
CIT0012
CIT0011
CIT0099
CIT0090
Nayak AK (CIT0048) 2010; 3
CIT0092
CIT0014
CIT0013
CIT0016
CIT0015
CIT0018
CIT0017
CIT0019
Kusters JG (CIT0032) 1997; 65
CIT0021
CIT0020
CIT0023
CIT0022
CIT0025
CIT0024
CIT0026
CIT0029
CIT0028
CIT0031
CIT0034
CIT0033
CIT0036
CIT0035
CIT0038
CIT0037
CIT0039
CIT0040
CIT0043
CIT0042
CIT0044
Rocca J (CIT0119) 2004; 97
CIT0047
CIT0046
CIT0049
Patel SS (CIT0066) 2006; 63
CIT0050
Tripathi G (CIT0056) 2010; 18
CIT0052
CIT0051
CIT0054
Shell JW. (CIT0041) 1996
CIT0053
CIT0055
Graham DY (CIT0010) 1996; 91
Nagahara N (CIT0091) 1998; 42
CIT0058
CIT0057
CIT0059
CIT0061
CIT0063
CIT0062
CIT0065
Marshall BJ (CIT0027) 1991; 86
CIT0064
CIT0067
CIT0100
CIT0109
CIT0069
CIT0102
CIT0068
CIT0101
CIT0104
CIT0103
CIT0106
CIT0105
CIT0108
References_xml – volume-title: Brock biology of microorganisms
  year: 2000
  ident: CIT0002
– volume: 43
  start-page: 2028
  year: 1982
  ident: CIT0045
  publication-title: Am J Vet Res
  doi: 10.2460/ajvr.1982.43.11.2028
– ident: CIT0116
  doi: 10.1016/S0939-6411(01)00124-2
– ident: CIT0012
  doi: 10.1136/gut.2003.022111
– ident: CIT0124
– ident: CIT0038
– ident: CIT0063
  doi: 10.1016/j.jsps.2011.01.004
– volume: 3
  start-page: 2
  year: 2010
  ident: CIT0048
  publication-title: Asian J Pharm Clin Res
– ident: CIT0016
  doi: 10.1016/j.dld.2005.03.007
– ident: CIT0103
  doi: 10.3109/10717544.2014.916766
– ident: CIT0064
  doi: 10.1208/s12249-008-9038-8
– ident: CIT0083
  doi: 10.1248/cpb.57.1068
– ident: CIT0131
  doi: 10.1016/j.biomaterials.2016.01.045
– ident: CIT0062
  doi: 10.3109/03639045.2015.1054397
– ident: CIT0036
  doi: 10.2217/fmb.10.25
– ident: CIT0058
– ident: CIT0120
  doi: 10.1007/BF02300360
– ident: CIT0088
  doi: 10.3109/02652048.2013.805840
– ident: CIT0006
  doi: 10.1016/S0168-1605(99)00160-9
– ident: CIT0023
  doi: 10.1046/j.1365-2036.2002.01165.x
– ident: CIT0105
  doi: 10.1016/j.ijpharm.2013.11.053
– ident: CIT0017
  doi: 10.1016/S1590-8658(01)80139-0
– ident: CIT0126
  doi: 10.1016/j.biomaterials.2013.02.028
– ident: CIT0009
  doi: 10.3109/00365529609094541
– ident: CIT0079
  doi: 10.1081/DMR-100104401
– volume: 15
  start-page: 243
  year: 1998
  ident: CIT0107
  publication-title: Crit Rev Ther Drug Carrier Syst
– ident: CIT0121
  doi: 10.1002/jbm.b.30134
– ident: CIT0051
  doi: 10.1208/pt060347
– ident: CIT0046
  doi: 10.1016/0168-3659(85)90061-6
– ident: CIT0070
– ident: CIT0092
  doi: 10.1080/107175400455173
– ident: CIT0087
  doi: 10.1016/j.colsurfb.2016.01.048
– ident: CIT0001
  doi: 10.1016/S0140-6736(84)91816-6
– ident: CIT0042
  doi: 10.1111/j.1083-4389.2004.00251.x
– ident: CIT0013
  doi: 10.1136/gutjnl-2012-302254
– ident: CIT0098
  doi: 10.1016/j.jconrel.2004.06.022
– ident: CIT0100
  doi: 10.1080/10717540260397837
– ident: CIT0014
  doi: 10.1097/00004836-200304000-00009
– ident: CIT0078
  doi: 10.1016/j.ijpharm.2015.04.004
– ident: CIT0090
  doi: 10.1016/j.jsps.2014.02.009
– ident: CIT0052
  doi: 10.1053/jinf.2002.1047
– ident: CIT0076
  doi: 10.3109/03639049409038361
– ident: CIT0112
  doi: 10.1016/j.ijpharm.2014.01.024
– ident: CIT0044
  doi: 10.1016/S0378-5173(98)00400-1
– ident: CIT0039
– ident: CIT0118
  doi: 10.1016/j.jconrel.2005.10.031
– ident: CIT0007
  doi: 10.1053/gast.1996.v111.agast961110521
– ident: CIT0129
  doi: 10.1016/j.actbio.2013.07.034
– ident: CIT0033
  doi: 10.1136/gut.2006.101634
– ident: CIT0095
  doi: 10.1081/PDT-120022154
– volume: 63
  start-page: 53
  year: 2006
  ident: CIT0066
  publication-title: Acta Pol Pharm
– ident: CIT0109
  doi: 10.1023/A:1018939512213
– ident: CIT0004
  doi: 10.1007/s10620-014-3063-0
– ident: CIT0102
  doi: 10.1111/jphp.12345
– ident: CIT0085
  doi: 10.3109/10837450903196843
– volume: 65
  start-page: 3672
  year: 1997
  ident: CIT0032
  publication-title: Infect Immun
  doi: 10.1128/IAI.65.9.3672-3679.1997
– ident: CIT0086
  doi: 10.1016/j.ijpharm.2013.12.052
– ident: CIT0071
  doi: 10.1016/j.ijpharm.2006.11.008
– ident: CIT0031
  doi: 10.1093/jac/34.6.1025
– ident: CIT0008
  doi: 10.1007/BF01964416
– volume: 261
  start-page: G827
  year: 1991
  ident: CIT0030
  publication-title: Am J Physiol
– ident: CIT0059
– ident: CIT0040
– ident: CIT0055
  doi: 10.1046/j.1365-2036.2003.01655.x
– ident: CIT0081
  doi: 10.1080/713840399
– ident: CIT0125
  doi: 10.1016/j.ijpharm.2014.04.070
– ident: CIT0019
  doi: 10.1046/j.1365-2036.2000.00846.x
– volume: 97
  start-page: 73
  year: 2004
  ident: CIT0119
  publication-title: Gattefossé Technical Bull
– ident: CIT0099
  doi: 10.1248/cpb.56.1412
– ident: CIT0122
  doi: 10.1163/156856209X415855
– ident: CIT0005
  doi: 10.1146/annurev.micro.54.1.615
– ident: CIT0111
– ident: CIT0049
  doi: 10.1021/mp5000339
– ident: CIT0003
  doi: 10.1093/oxfordjournals.epirev.a018040
– ident: CIT0127
  doi: 10.1016/j.actbio.2010.08.028
– ident: CIT0020
  doi: 10.1016/S1590-8658(03)00432-8
– ident: CIT0108
– ident: CIT0029
  doi: 10.4292/wjgpt.v3.i4.68
– ident: CIT0104
  doi: 10.1016/j.ejpb.2015.07.020
– ident: CIT0113
  doi: 10.1211/0022357011775163
– ident: CIT0077
– ident: CIT0025
  doi: 10.1046/j.1365-2036.2000.00719.x
– ident: CIT0110
  doi: 10.1023/A:1015981627525
– ident: CIT0034
  doi: 10.7326/0003-4819-148-12-200806170-00226
– ident: CIT0050
  doi: 10.1002/jps.2600770802
– volume: 86
  start-page: 16
  year: 1991
  ident: CIT0027
  publication-title: Am J Gastroenterol
– ident: CIT0117
  doi: 10.1016/S0168-3659(99)00139-X
– ident: CIT0073
  doi: 10.1007/BF03259398
– ident: CIT0068
– ident: CIT0065
  doi: 10.1208/s12249-012-9882-4
– ident: CIT0054
  doi: 10.1016/S0168-3659(97)00266-6
– ident: CIT0061
  doi: 10.1358/mf.2006.28.7.1003574
– volume: 18
  start-page: 247
  year: 2010
  ident: CIT0056
  publication-title: DARU
– ident: CIT0037
  doi: 10.1159/000236024
– ident: CIT0057
– ident: CIT0128
  doi: 10.1016/j.procbio.2012.05.019
– ident: CIT0018
  doi: 10.1046/j.1365-2036.2002.01169.x
– ident: CIT0074
– ident: CIT0022
  doi: 10.1111/j.1365-2036.2005.02522.x
– ident: CIT0015
  doi: 10.1111/j.1365-2036.2004.02077.x
– ident: CIT0035
  doi: 10.4166/kjg.2014.63.2.82
– ident: CIT0082
  doi: 10.2478/v10007-007-0033-5
– ident: CIT0026
  doi: 10.1016/j.dld.2004.09.008
– ident: CIT0096
  doi: 10.1016/S0939-6411(03)00097-3
– ident: CIT0115
  doi: 10.1016/0168-3659(96)01344-2
– ident: CIT0011
  doi: 10.1111/j.1365-2036.2005.02656.x
– volume: 26
  start-page: 541
  year: 1991
  ident: CIT0060
  publication-title: Acta Pharm Sin
– ident: CIT0094
  doi: 10.1016/S0378-5173(01)00985-1
– ident: CIT0101
  doi: 10.1002/app.24319
– ident: CIT0053
  doi: 10.1016/0016-5085(85)90342-7
– ident: CIT0047
  doi: 10.1016/S0168-3659(99)00204-7
– ident: CIT0067
  doi: 10.1002/mabi.200600164
– ident: CIT0069
– ident: CIT0072
  doi: 10.1016/j.jconrel.2007.07.011
– ident: CIT0043
  doi: 10.1517/17425247.3.2.217
– ident: CIT0114
  doi: 10.1016/0168-3659(96)01343-0
– ident: CIT0021
  doi: 10.1111/j.1523-5378.2006.00407.x
– ident: CIT0084
  doi: 10.1208/s12249-009-9231-4
– ident: CIT0024
  doi: 10.1111/j.1365-2036.2005.02412.x
– volume: 42
  start-page: 2492
  year: 1998
  ident: CIT0091
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.42.10.2492
– ident: CIT0075
– ident: CIT0028
  doi: 10.1046/j.1365-2036.2000.00791.x
– ident: CIT0093
  doi: 10.1016/j.ijpharm.2003.12.026
– ident: CIT0130
  doi: 10.1021/bm5012618
– ident: CIT0097
  doi: 10.1016/j.ijpharm.2003.12.001
– ident: CIT0106
– ident: CIT0080
  doi: 10.1021/mp500242q
– ident: CIT0123
  doi: 10.1021/mp800193n
– volume: 91
  start-page: 1072
  year: 1996
  ident: CIT0010
  publication-title: Am J Gastroenterol
– volume-title: Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
  year: 1996
  ident: CIT0041
– ident: CIT0089
  doi: 10.1208/s12249-011-9730-y
SSID ssj0013610
Score 2.2709749
SecondaryResourceType review_article
Snippet Helicobacter pylori have been subject to intense investigation since its discovery from gastric biopsy in 1982. This gastropathogen has been regarded as...
SourceID pubmed
crossref
informaworld
SourceType Index Database
Enrichment Source
Publisher
StartPage 897
SubjectTerms Adhesive systems
Antacids - administration & dosage
Antacids - pharmacokinetics
Antacids - therapeutic use
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - therapeutic use
Drug Delivery Systems - methods
Drug Resistance, Multiple, Bacterial
Drug Therapy, Combination
Gastric Mucosa - drug effects
Gastric Mucosa - metabolism
Gastric Mucosa - microbiology
GRDDS
H. pylori
Helicobacter Infections - drug therapy
Helicobacter Infections - microbiology
Helicobacter pylori - drug effects
Humans
in situ gelling systems
polymeric rafts
Proton Pump Inhibitors - administration & dosage
Proton Pump Inhibitors - pharmacokinetics
Proton Pump Inhibitors - therapeutic use
Title Helicobacter pylori: past, current and future treatment strategies with gastroretentive drug delivery systems
URI https://www.tandfonline.com/doi/abs/10.3109/1061186X.2016.1171326
https://www.ncbi.nlm.nih.gov/pubmed/27027827
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9swFBZZ-7KXsfu6bkMPoy-JO9tyZHtv7bpSChulpNA3Y1lSWuiykNiF9L_sv-4cH_nSrLsTcIISWcbfl6Nz5HM-MfY2yGWY6th4Y2FjCFAi7aW-8b0osiIshM7jHAPFT5_l0Vl0fD4-Hwy-9bKWqlLtFjd31pX8C6rQBrhilexfINueFBrgM-ALR0AYjn-EMcwZAKSqBZeHcwy9MeFtOM-pkKNw2ku4Nk7aIb288mXZiETQWuwUOi2wphHTh67NUC-q6VDDAHBXVk7wefkTV7b-LeWUNzMh7uGFRp-SJqtF3jYfVIqWyY-ri8tuKXZK-r-n-UV1BcduujiFCwP7XCfk5rh_9nV_pSKQWLJHVc01tyY_bBrSs7vgVnhBUm9qCNOSawtTLxTusY0z1lRw3ZDS75nehPJ83SyeUpHo-gQhSF8Vh8PRMLVP4nNriMnXBLkpQqJv7rHNEKIQMKObe_sH-4fdYyrp5C7c1VOJGA7y7s4hbjk_t6Rx16Ka2ruZPGQPHJZ8jzj2iA3M7DHbOSFd89WIT7oyveWI7_CTTvF89YR96RORExHfc6ThiDsSciAhJxLyloS8IyFHEvI1EnIkFm9IyB0Jn7Kzw4-TD0ee28fDK4SUpSdVLEQRhwoMhlA6jJSfwsvkKjBSJVopE2l4H9fRugantkgi61sbykImgRXP2Mbs68y8YFwF0VjECpx4mcCPi9TGRoSBThJldWzNFouaG5wVTuQe91q5yiDYRVyyBpcMcckcLltst-02J5WX33VI--hlZc1tS7TGfr_s-5ygbofCmlDw1OOX_3HWbXa_-8-9YhvlojKvwV8u1RvH2u9zMr7a
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Helicobacter+pylori%3A+past%2C+current+and+future+treatment+strategies+with+gastroretentive+drug+delivery+systems&rft.jtitle=Journal+of+drug+targeting&rft.au=Verma%2C+Anurag&rft.au=Dubey%2C+Juhi&rft.au=Hegde%2C+Rahul+Rama&rft.au=Rastogi%2C+Vaibhav&rft.date=2016-11-25&rft.pub=Taylor+%26+Francis&rft.issn=1061-186X&rft.eissn=1029-2330&rft.volume=24&rft.issue=10&rft.spage=897&rft.epage=915&rft_id=info:doi/10.3109%2F1061186X.2016.1171326&rft.externalDocID=1171326
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1061-186X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1061-186X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1061-186X&client=summon